Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ABHD14A-ACY1 readthrough (ABHD14A-ACY1)
- Target
- ABHD14A-ACY1
- Molecular classification
- Other (readthrough transcript, often non-coding), Histone modification (associated with gene, not protein), Protein-coding (Controversial, likely not functional)
01
Overview
ABHD14A-ACY1 readthrough is a naturally occurring transcript resulting from readthrough between the adjacent ABHD14A (abhydrolase domain containing 14A) and ACY1 (aminoacylase 1) genes on chromosome 3. This transcript is generally believed to be non-protein coding, subject to nonsense-mediated decay, and does not correspond to a functional protein product. Some databases annotate it as protein-coding, but the evidence is inconsistent, and no biological, mechanistic, or therapeutic roles have been established. Its annotations and associations typically derive from the parent genes; ACY1 is a cytosolic zinc-binding enzyme involved in acyl-amino acid metabolism and is clinically relevant for aminoacylase 1 deficiency, but those functional roles do not apply to the ABHD14A-ACY1 readthrough transcript itself.
- Other names
- ABHD14A-ACY1 readthrough (NMD candidate)ABHD14A-ACY1 readthrough (non-protein coding)ABHD14A-ACY1HGNC:38856NCBI Gene:100526760Ensembl: ENSG00000114786UniProt: A0A1B0GUT4UniProt: F2Z3Q0
02
Mechanism of action
None reported, as there are no drugs targeting this transcript.
03
Biological functions
No direct biological function established for the readthrough transcript itselfLikely regulatory or non-functional due to rapid degradation (NMD candidate)Annotations reflect parent genes: hydrolase activity, aminoacylase activity are related to ACY1, not ABHD14A-ACY1 readthrough
04
Disease associations
No established roles for the readthrough transcriptAminoacylase 1 deficiency relates to ACY1 function, not the readthrough transcriptNo roles in cancer, inflammation, neurodegenerative disease, cardiovascular disease, infection, or other disease models
05
Safety considerations
None reported
06
Interacting drugs
None
07
Biomarkers
None established
Beyond the preview
Go deeper on ABHD14A-ACY1 readthrough (ABHD14A-ACY1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ABHD14A-ACY1 readthrough (ABHD14A-ACY1).